Literature DB >> 35855703

Cancer: A pathologist's journey from morphology to molecular.

Kavita Sahai1, Ankur Ahuja2.   

Abstract

The journey of cancer has taken significant positive steps towards better diagnosis and management. Pathologists have taken a leading role in this journey. Started with morphology which itself went through substantial developments in knowing the aetiology, pathogenesis, classification based upon the pattern, cellular details of the cancer. However, the histomorphologists met some road blocks in the form of ambiguities and some limitations that led to the expansion of pathologist's field to various other ancillary tests to enhance its values form diagnosis to therapeutics. This new journey facilitated the confidence of pathologist in the diagnosis, expanded their role in the clinical management through targeted therapy, monitoring of drugs, suggestions of prognosis. Various molecular diagnostic tests have been developed for the identification of tumor molecular profile for exploration of targeted therapy. The major problems in the management of cancer were resistance to chemotherapy, relapses and wide-spread side effects of chemotherapy. All these major problems to some extents are getting resolved with time as the molecular profiling is opening the gates. Many questions are being answered with the evolution in pathology. With the revolution of targeted therapy many difficult cancers are being treated with fewer side effects. In this review we will go through the journey from histomorphology, its advancement, digital pathology to the molecular pathology. These advancements interestingly haven't replaced the other, rather have enhanced others for the better management of cancer.
© 2022 Director General, Armed Forces Medical Services. Published by Elsevier, a division of RELX India Pvt. Ltd.

Entities:  

Keywords:  Histomorphology; Immunohistochemistry; Molecular pathology; Next generation sequencing; Targeted therapy

Year:  2022        PMID: 35855703      PMCID: PMC9287647          DOI: 10.1016/j.mjafi.2022.06.009

Source DB:  PubMed          Journal:  Med J Armed Forces India        ISSN: 0377-1237


  49 in total

1.  Initial sequencing and analysis of the human genome.

Authors:  E S Lander; L M Linton; B Birren; C Nusbaum; M C Zody; J Baldwin; K Devon; K Dewar; M Doyle; W FitzHugh; R Funke; D Gage; K Harris; A Heaford; J Howland; L Kann; J Lehoczky; R LeVine; P McEwan; K McKernan; J Meldrim; J P Mesirov; C Miranda; W Morris; J Naylor; C Raymond; M Rosetti; R Santos; A Sheridan; C Sougnez; Y Stange-Thomann; N Stojanovic; A Subramanian; D Wyman; J Rogers; J Sulston; R Ainscough; S Beck; D Bentley; J Burton; C Clee; N Carter; A Coulson; R Deadman; P Deloukas; A Dunham; I Dunham; R Durbin; L French; D Grafham; S Gregory; T Hubbard; S Humphray; A Hunt; M Jones; C Lloyd; A McMurray; L Matthews; S Mercer; S Milne; J C Mullikin; A Mungall; R Plumb; M Ross; R Shownkeen; S Sims; R H Waterston; R K Wilson; L W Hillier; J D McPherson; M A Marra; E R Mardis; L A Fulton; A T Chinwalla; K H Pepin; W R Gish; S L Chissoe; M C Wendl; K D Delehaunty; T L Miner; A Delehaunty; J B Kramer; L L Cook; R S Fulton; D L Johnson; P J Minx; S W Clifton; T Hawkins; E Branscomb; P Predki; P Richardson; S Wenning; T Slezak; N Doggett; J F Cheng; A Olsen; S Lucas; C Elkin; E Uberbacher; M Frazier; R A Gibbs; D M Muzny; S E Scherer; J B Bouck; E J Sodergren; K C Worley; C M Rives; J H Gorrell; M L Metzker; S L Naylor; R S Kucherlapati; D L Nelson; G M Weinstock; Y Sakaki; A Fujiyama; M Hattori; T Yada; A Toyoda; T Itoh; C Kawagoe; H Watanabe; Y Totoki; T Taylor; J Weissenbach; R Heilig; W Saurin; F Artiguenave; P Brottier; T Bruls; E Pelletier; C Robert; P Wincker; D R Smith; L Doucette-Stamm; M Rubenfield; K Weinstock; H M Lee; J Dubois; A Rosenthal; M Platzer; G Nyakatura; S Taudien; A Rump; H Yang; J Yu; J Wang; G Huang; J Gu; L Hood; L Rowen; A Madan; S Qin; R W Davis; N A Federspiel; A P Abola; M J Proctor; R M Myers; J Schmutz; M Dickson; J Grimwood; D R Cox; M V Olson; R Kaul; C Raymond; N Shimizu; K Kawasaki; S Minoshima; G A Evans; M Athanasiou; R Schultz; B A Roe; F Chen; H Pan; J Ramser; H Lehrach; R Reinhardt; W R McCombie; M de la Bastide; N Dedhia; H Blöcker; K Hornischer; G Nordsiek; R Agarwala; L Aravind; J A Bailey; A Bateman; S Batzoglou; E Birney; P Bork; D G Brown; C B Burge; L Cerutti; H C Chen; D Church; M Clamp; R R Copley; T Doerks; S R Eddy; E E Eichler; T S Furey; J Galagan; J G Gilbert; C Harmon; Y Hayashizaki; D Haussler; H Hermjakob; K Hokamp; W Jang; L S Johnson; T A Jones; S Kasif; A Kaspryzk; S Kennedy; W J Kent; P Kitts; E V Koonin; I Korf; D Kulp; D Lancet; T M Lowe; A McLysaght; T Mikkelsen; J V Moran; N Mulder; V J Pollara; C P Ponting; G Schuler; J Schultz; G Slater; A F Smit; E Stupka; J Szustakowki; D Thierry-Mieg; J Thierry-Mieg; L Wagner; J Wallis; R Wheeler; A Williams; Y I Wolf; K H Wolfe; S P Yang; R F Yeh; F Collins; M S Guyer; J Peterson; A Felsenfeld; K A Wetterstrand; A Patrinos; M J Morgan; P de Jong; J J Catanese; K Osoegawa; H Shizuya; S Choi; Y J Chen; J Szustakowki
Journal:  Nature       Date:  2001-02-15       Impact factor: 49.962

Review 2.  PD-1/PD-L1 inhibitors.

Authors:  Joel Sunshine; Janis M Taube
Journal:  Curr Opin Pharmacol       Date:  2015-06-02       Impact factor: 5.547

Review 3.  Quantitative in situ proteomics; a proposed pathway for quantification of immunohistochemistry at the light-microscopic level.

Authors:  Clive R Taylor
Journal:  Cell Tissue Res       Date:  2015-01-27       Impact factor: 5.249

Review 4.  Sequence artifacts in DNA from formalin-fixed tissues: causes and strategies for minimization.

Authors:  Hongdo Do; Alexander Dobrovic
Journal:  Clin Chem       Date:  2014-11-24       Impact factor: 8.327

5.  Therapeutic strategies to overcome crizotinib resistance in non-small cell lung cancers harboring the fusion oncogene EML4-ALK.

Authors:  Ryohei Katayama; Tahsin M Khan; Cyril Benes; Eugene Lifshits; Hiromichi Ebi; Victor M Rivera; William C Shakespeare; A John Iafrate; Jeffrey A Engelman; Alice T Shaw
Journal:  Proc Natl Acad Sci U S A       Date:  2011-04-18       Impact factor: 11.205

Review 6.  Predictive molecular pathology and its role in targeted cancer therapy: a review focussing on clinical relevance.

Authors:  M Dietel; K Jöhrens; Mv Laffert; M Hummel; H Bläker; B M Müller; A Lehmann; C Denkert; F L Heppner; A Koch; C Sers; I Anagnostopoulos
Journal:  Cancer Gene Ther       Date:  2013-03-15       Impact factor: 5.987

Review 7.  Predictive genomics: a cancer hallmark network framework for predicting tumor clinical phenotypes using genome sequencing data.

Authors:  Edwin Wang; Naif Zaman; Shauna Mcgee; Jean-Sébastien Milanese; Ali Masoudi-Nejad; Maureen O'Connor-McCourt
Journal:  Semin Cancer Biol       Date:  2014-04-18       Impact factor: 15.707

Review 8.  Translation of the Philadelphia chromosome into therapy for CML.

Authors:  Brian J Druker
Journal:  Blood       Date:  2008-12-15       Impact factor: 22.113

Review 9.  Imatinib: a breakthrough of targeted therapy in cancer.

Authors:  Nida Iqbal; Naveed Iqbal
Journal:  Chemother Res Pract       Date:  2014-05-19

Review 10.  Worse outcome in breast cancer with higher tumor-infiltrating FOXP3+ Tregs : a systematic review and meta-analysis.

Authors:  Jiafeng Shou; Zhigang Zhang; Yucheng Lai; Zhigang Chen; Jian Huang
Journal:  BMC Cancer       Date:  2016-08-26       Impact factor: 4.430

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.